新型冠状病毒病的抗病毒药物研究进展

Progress of antiviral drugs in coronavirus disease 2019(COVID-19)

目的:总结分析新型冠状病毒病(coronavirus disease 2019,COVID-19)的抗病毒治疗试用药物,为优化临床治疗提供参考。方法:根据《新型冠状病毒肺炎诊疗方案(试行第七版)》《上海市2019冠状病毒病综合救治专家共识》以及《军队支援湖北医疗队新型冠状病毒感染疾病诊疗方案》中已发布的抗病毒药物,包括ɑ-干扰素、洛匹那韦/利托那韦、利巴韦林、磷酸氯喹、阿比多尔、法匹拉韦,以及瑞德西韦,结合相关文献对其作用机制、循证依据等进行总结分析。结论:对SARS-CoV-2的抗病毒药物的认识需经多项临床研究评价进一步明确,特殊试用阶段应注意加强药学监护,从而提高临床治疗的安全性、有效性。

Objective:To summarize and analyze antiviral trial drugs for the treatment of coronavirus disease 2019,and provide reference for optimizing clinical treatment.Medthods:According to the antiviral drugs already published in the "COVID-19 Diagnosis and Treatment Plan(Trial implementation of the seventh edition)","Shanghai 2019 Coronavirus Comprehensive Treatment Expert Consensus" and "Military Support Hubei Medical Team novel coronavirus Infection Disease Diagnosis and Treatment Plan",including α-interferon,lopinavir/ritonavir,ribavirin,chloroquine phosphate,arbidol,favipiravir,and remdesivir,the mechanism of action and evidence-based basis of the drugs were summarized and analyzed in combination with relevant literature.Results:Understanding of antiviral drugs for SARS-CoV-2 needs to be further clarified through a number of clinical studies and evaluations,and attention should be paid to strengthening pharmaceutical care during the special trial phase,so as to improve the safety and effectiveness of clinical treatment.